Moxaclav® is a combination antibiotic containing Amoxicillin (125 mg/5 ml) and Clavulanic Acid (31.25 mg/5 ml). Manufactured by Square Pharmaceuticals Ltd., this formulation is presented as a dry powder that, upon reconstitution with water, yields a 100 ml oral suspension. It is designed to combat a broad spectrum of bacterial infections by inhibiting bacterial cell wall synthesis and counteracting beta-lactamase enzymes that some bacteria produce to resist antibiotics.